REFILE-Teva's turnaround CEO sets sights on $40 bln mega-deal

April 22, 2015 1:10 PM

26 0

TEL AVIV, April 22 (Reuters) - Israeli turnaround specialist Erez Vigodman, the chief executive of Teva Pharmaceutical Industries, is looking to pull off the ultimate transformation with the biggest deal in Israel's corporate history.

His unsolicited $40 billion offer for smaller generic drug rival Mylan Inc is Vigodman's attempt to turn Teva into a global drug powerhouse with a $100 billion market valuation, a far cry from its start as a small wholesale drug business in Jerusalem more than a century ago.

Read more

To category page